Last update 08 May 2025

ADRA1 x β-adrenoceptors x DNA

Basic Info

Related Targets
ADRA1β-adrenoceptorsDNA

Related

1
Drugs associated with ADRA1 x β-adrenoceptors x DNA
Cisplatin/Epinephrine
Target
ADRA1 x DNA x β-adrenoceptors
Mechanism
ADRA1 agonists [+5]
Active Org.-
Originator Org.
Novartis Pharma AG
Active Indication-
Inactive Indication
Breast Cancer [+8]
Drug Highest PhasePending
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
1
Clinical Trials associated with ADRA1 x β-adrenoceptors x DNA
NCT00002659
/ Unknown statusPhase 3
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECT OF CISPLATIN/EPINEPHRINE INJECTABLE GEL (PRODUCT MPI 5010) WHEN ADMINISTERED INTRATUMORALLY FOR ACHIEVEMENT OF TREATMENT GOALS IN RECURRENT OR REFRACTORY SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
100 Clinical Results associated with ADRA1 x β-adrenoceptors x DNA
Login to view more data
100 Translational Medicine associated with ADRA1 x β-adrenoceptors x DNA
Login to view more data
0 Patents (Medical) associated with ADRA1 x β-adrenoceptors x DNA
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free